Scholarlink

<p>This study aimed to obtain data describing the epidemiology and antifungal susceptibility of yeasts isolated from bloodstream infections (BSI) in the Czech Republic (CR). This study presents data from the first year of a national, long-term surveillance program. All microbiologically confirmed candidemia cases in patients hospitalized at 30 Czech centers in 2023 were evaluated. This study assessed BSI incidence per 100,000 inhabitants, species distribution, and antifungal susceptibilities (EUCAST E.Def 7.4 protocol) of strains.aff Whole-genome sequencing was performed on selected isolates with acquired resistance or non-wild-type phenotypes to determine the molecular mechanisms of resistance. In total, 433 isolates from 408 unique BSI episodes in 398 patients were recorded in 2023. <i>Candida albicans</i> was the most frequent species (40.6%), followed by <i>Candida glabrata</i> (24.5%), <i>Candida parapsilosis</i> (14.5%), and <i>Candida tropicalis</i> (5.5%). In pediatric patients, <i>C. albicans</i> (58.8%) was the most common, followed by <i>C. parapsilosis</i> (17.6%). <i>Candida auris</i> BSI was not detected in 2023. The highest rates of acquired fluconazole resistance were detected in <i>C. parapsilosis</i> (16.9%) and <i>C. glabrata</i> (15.4%). Most fluconazole-resistant (FLC-R) <i>C. parapsilosis</i> isolates carried Y132F mutation in <i>ERG</i>11 gene (14/15; 93.3%). One isolate of <i>C. glabrata</i> was resistant to echinocandins (1.3%), but remained susceptible to azoles, mutations in FKS1 (G14S) and FKS2 (S663P, T926P) were identified. This nationwide survey provides the first comprehensive yeast BSI surveillance data from the Czech Republic, which spans the entire country. CR follows trends observed in developed countries, with a decline in <i>C. albicans</i> and a rise in <i>C. glabrata</i> infections. To our knowledge, this is the first report describing FLC-R <i>C. parapsilosis</i> isolates carrying the Y132F <i>ERG</i>11 mutation in CR. These findings highlight several emerging challenges that reflect global trends: a shifting spectrum of <i>Candida</i> species from <i>C. albicans</i> to non-<i>albicans</i> species, and rising levels of acquired azole resistance. Therefore, continuous national monitoring is essential.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

National Surveillance of Candidemia in the Czech Republic: Preliminary Results from the 2023 Multicentre Study

  • 期刊论文

  • 发表日期：

    2026年5月4日

查看全文
  • Pavlína Lysková,
  • Radim Dobiáš,
  • Matěj Bezdíček,
  • Vít Hubka,
  • Petra Sumerauerová,
  • Daniela Lžičařová,
  • Iva Kocmanová,
  • Vladimír Buchta,
  • Ivana Prošková,
  • Helena Janouškovcová,
  • Petra Olišarová,
  • Kateřina Svobodová,
  • Petr Hamal,
  • Naďa Mallátová,
  • Zuzana Kadlečková,
  • Johana Kučerová,
  • Markéta Skružná,
  • Filip Růžička,
  • Marta Fridrichová,
  • Daniela Fáčková,
  • Markéta Hajná,
  • Jana Kunzová,
  • Jan Kubele,
  • Zuzana Zemanová,
  • Miroslava Dlouhá,
  • Lenka Šemberová,
  • Daniela Balíková,
  • Galina Eliášová,
  • Alena Steinerová,
  • Filip Prusík,
  • Romana Filová,
  • Šárka Lásiková,
  • Iva Nikodýmová,
  • Iveta Pěkníková,
  • Eva Kašperová,
  • Martina Čurdová,
  • Hana Tomášková,
  • Hana Slepčanová,
  • Miroslav Kolařík

摘要

This study aimed to obtain data describing the epidemiology and antifungal susceptibility of yeasts isolated from bloodstream infections (BSI) in the Czech Republic (CR). This study presents data from the first year of a national, long-term surveillance program. All microbiologically confirmed candidemia cases in patients hospitalized at 30 Czech centers in 2023 were evaluated. This study assessed BSI incidence per 100,000 inhabitants, species distribution, and antifungal susceptibilities (EUCAST E.Def 7.4 protocol) of strains.aff Whole-genome sequencing was performed on selected isolates with acquired resistance or non-wild-type phenotypes to determine the molecular mechanisms of resistance. In total, 433 isolates from 408 unique BSI episodes in 398 patients were recorded in 2023. Candida albicans was the most frequent species (40.6%), followed by Candida glabrata (24.5%), Candida parapsilosis (14.5%), and Candida tropicalis (5.5%). In pediatric patients, C. albicans (58.8%) was the most common, followed by C. parapsilosis (17.6%). Candida auris BSI was not detected in 2023. The highest rates of acquired fluconazole resistance were detected in C. parapsilosis (16.9%) and C. glabrata (15.4%). Most fluconazole-resistant (FLC-R) C. parapsilosis isolates carried Y132F mutation in ERG11 gene (14/15; 93.3%). One isolate of C. glabrata was resistant to echinocandins (1.3%), but remained susceptible to azoles, mutations in FKS1 (G14S) and FKS2 (S663P, T926P) were identified. This nationwide survey provides the first comprehensive yeast BSI surveillance data from the Czech Republic, which spans the entire country. CR follows trends observed in developed countries, with a decline in C. albicans and a rise in C. glabrata infections. To our knowledge, this is the first report describing FLC-R C. parapsilosis isolates carrying the Y132F ERG11 mutation in CR. These findings highlight several emerging challenges that reflect global trends: a shifting spectrum of Candida species from C. albicans to non-albicans species, and rising levels of acquired azole resistance. Therefore, continuous national monitoring is essential.